Reneo Pharmaceuticals Financials
RPHM Stock | USD 1.66 0.01 0.61% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 12.07 | 13.44 |
|
|
The financial analysis of Reneo Pharmaceuticals is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Reneo Pharmaceuticals includes many different criteria found on its balance sheet. For example, investors should never minimize Reneo Pharmaceuticals' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Reneo Pharmaceuticals' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Reneo Pharmaceuticals.
Net Income |
|
With this module, you can analyze Reneo financials for your investing period. You should be able to track the changes in Reneo Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Reneo | Select Account or Indicator |
Understanding current and past Reneo Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Reneo Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Reneo Pharmaceuticals' assets may result in an increase in income on the income statement.
Evaluating Reneo Pharmaceuticals' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Reneo Pharmaceuticals' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Reneo Pharmaceuticals' relative financial performance
Chance Of Distress
Less than 21
100 | Zero |
Low
Reneo Pharmaceuticals has less than 21 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Reneo Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Reneo Pharmaceuticals' odds of distress score SHOULD NOT be confused with the real chance of Reneo Pharmaceuticals filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Reneo is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Reneo Pharmaceuticals' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More InfoThe data published in Reneo Pharmaceuticals' official financial statements usually reflect Reneo Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Reneo Pharmaceuticals. For example, before you start analyzing numbers published by Reneo accountants, it's critical to develop an understanding of what Reneo Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Reneo Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Reneo Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Reneo Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Reneo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Reneo Pharmaceuticals' management manipulating its earnings.
Reneo Pharmaceuticals Company Summary
Reneo Pharmaceuticals competes with Mustang Bio, and YS Biopharma. Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US75974E1038 |
CUSIP | 75974E103 |
Location | California; U.S.A |
Business Address | 18575 Jamboree Road, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | NYSE Composite |
Website | reneopharma.com |
Phone | 858 283 0280 |
Currency | USD - US Dollar |
You should never invest in Reneo Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Reneo Stock, because this is throwing your money away. Analyzing the key information contained in Reneo Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Reneo Pharmaceuticals Key Financial Ratios
Generally speaking, Reneo Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Reneo Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Reneo Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Reneo Pharmaceuticals reports annually and quarterly.Return On Equity | -0.59 | ||||
EBITDA | (72.46 M) | ||||
Net Income | (67.43 M) |
Reneo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Reneo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reneo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reneo Pharmaceuticals competition to find correlations between indicators driving Reneo Pharmaceuticals's intrinsic value. More Info.Reneo Pharmaceuticals is rated second in book value per share category among related companies. It is currently regarded as top stock in shares owned by institutions category among related companies producing about 24.29 of Shares Owned By Institutions per Book Value Per Share. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Reneo Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Reneo Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reneo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Reneo Pharmaceuticals Systematic Risk
Reneo Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Reneo Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Reneo Pharmaceuticals correlated with the market. If Beta is less than 0 Reneo Pharmaceuticals generally moves in the opposite direction as compared to the market. If Reneo Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Reneo Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Reneo Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Reneo Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Reneo Pharmaceuticals Financials
What exactly are Reneo Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Reneo Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Reneo Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Reneo Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Reneo Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Reneo Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Reneo Pharmaceuticals Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Reneo Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Reneo has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Reneo Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Reneo Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Reneo Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Reneo Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Reneo Pharmaceuticals' stock is overvalued or undervalued.
Today, most investors in Reneo Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Reneo Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Reneo Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Reneo Pharmaceuticals March 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Reneo Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Reneo Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Reneo Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Reneo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Reneo Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 1.72 | |||
Information Ratio | 0.0707 | |||
Maximum Drawdown | 22.19 | |||
Value At Risk | (2.94) | |||
Potential Upside | 3.75 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reneo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in Reneo Stock, please use our How to Invest in Reneo Pharmaceuticals guide.Note that the Reneo Pharmaceuticals information on this page should be used as a complementary analysis to other Reneo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Reneo Stock analysis
When running Reneo Pharmaceuticals' price analysis, check to measure Reneo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reneo Pharmaceuticals is operating at the current time. Most of Reneo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reneo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reneo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reneo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Reneo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reneo Pharmaceuticals. If investors know Reneo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reneo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.36) | Return On Assets (0.36) | Return On Equity (0.59) |
The market value of Reneo Pharmaceuticals is measured differently than its book value, which is the value of Reneo that is recorded on the company's balance sheet. Investors also form their own opinion of Reneo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reneo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reneo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reneo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reneo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.